BioNexus Gene Lab Corp. (BGLC)
NASDAQ: BGLC · Real-Time Price · USD
2.180
+0.010 (0.46%)
At close: Apr 15, 2026, 4:00 PM EDT
2.250
+0.070 (3.21%)
After-hours: Apr 15, 2026, 6:45 PM EDT
BioNexus Gene Lab Employees
BioNexus Gene Lab had 30 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
30
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$247,497
Profits / Employee
-$99,487
Market Cap
5.15M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 30 | 0 | - | 30 | 0 |
| Dec 31, 2023 | 30 | -3 | -9.09% | 30 | 0 |
| Dec 31, 2022 | 33 | 1 | 3.13% | 27 | 6 |
| Dec 31, 2021 | 32 | -75 | -70.09% | 27 | 5 |
| Dec 31, 2020 | 107 | 98 | 1,088.89% | 99 | 8 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| FutureFuel | 493 |
| Northern Technologies International | 272 |
| Aemetis | 220 |
| Montauk Renewables | 189 |
| Bon Natural Life | 96 |
| J-Star Holding | 65 |
| Flexible Solutions International | 45 |
| Loop Industries | 40 |
BGLC News
- 5 weeks ago - BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform - GlobeNewsWire
- 7 weeks ago - BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman - GlobeNewsWire
- 2 months ago - BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN's Multi-Billion Dollar Market - GlobeNewsWire
- 4 months ago - BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for VitaGuard™ - GlobeNewsWire
- 4 months ago - BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization - GlobeNewsWire
- 4 months ago - BioNexus Gene Lab Corp. (Nasdaq: BGLC) and Fidelion Diagnostics Execute Exclusive Southeast Asia License for VitaGuard™ MRD Platform as Part of Strategic Alliance with Tongshu Gene - GlobeNewsWire
- 5 months ago - BioNexus Gene Lab Corp. (Nasdaq: BGLC) Announces Strategic Agreements with Fidelion Diagnostics for Southeast Asia MRD Commercialization - GlobeNewsWire
- 5 months ago - BioNexus Gene Lab Corp. Files $100 Million Shelf Registration and Establishes $20 Million At-the-Market Program to Advance Strategic Growth Opportunities - GlobeNewsWire